You have 9 free searches left this month | for more free features.

Programmed Cell Death-1 (PD1, PD-1)

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Donafenib Trial in Shanghai (Donafenib, PD-1, TACE)

Recruiting
  • Donafenib
  • Donafenib, PD-1
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University,
Mar 4, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

Recruiting
  • Urothelial Carcinoma
  • Zilovertamab vedotin
  • Cleveland, Ohio
  • +11 more
Jan 25, 2023

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

Lichen Planus Trial in Cairo (Skin Biopsy)

Not yet recruiting
  • Lichen Planus
  • Skin Biopsy
  • Cairo, Egypt
    Cairo University
May 14, 2021

Tumors Trial in United States (Niraparib, Pembrolizumab, TSR-042 (Dostarlimab))

Completed
  • Neoplasms
  • Whittier, Alaska
  • +15 more
Aug 29, 2022

Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

Recruiting
  • Peripheral T-cell Lymphoma
  • PD-1 antibody+ HDAC inhibitor
  • Shanghai, Shanghai, China
    Dongmei Ji
Dec 3, 2021

NSCLC Trial (Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Drug-eluting beads bronchial arterial chemoembolization
  • Programmed Cell Death Protein 1 Inhibitor
  • (no location specified)
Feb 17, 2022

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma Trial in New York (Nivolumab, Atezolizumab, Radiation &

Terminated
  • Metastatic Renal Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • New York, New York
    Weill Cornell Medicine - New York Presbyterian Hospital
Aug 26, 2021

EBV Infection Trial in Suzhou (PD-1 mAb)

Recruiting
  • EBV Infection
  • PD-1 monoclonal antibody
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 1, 2021

Safety of ICIs and TKIs Therapy for HCC

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Lenvatinib Oral Product
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Jun 11, 2022

Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent

Recruiting
  • Cervical Carcinoma
  • +8 more
  • Camrelizumab plus Concurrent chemoradiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 5, 2022

Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor Trial in Hangzhou (PD-1 immune

Recruiting
  • Plaque, Atherosclerotic
  • +4 more
  • PD-1 immune checkpoint blockades
  • Hangzhou, Zhejiang, China
    The Second Affiliated Hospital of Zhejiang University, School of
Nov 16, 2021

Recurrent/ Advanced Stage Endometrial Cancer Patients Trial in Guangzhou (Niraparib in Combination With Anti-PD1 Antibody)

Recruiting
  • Recurrent/ Advanced Stage Endometrial Cancer Patients
  • Niraparib in Combination With Anti-PD1 Antibody
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Aug 20, 2021

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor Trial in

Suspended
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 23, 2022

Advanced or Unresectable Melanoma Progressing After PD1 Blockade Trial in Norway, United States (ONCOS-102, Cyclophosphamide,

Completed
  • Advanced or Unresectable Melanoma Progressing After PD1 Blockade
  • ONCOS-102
  • +2 more
  • Baltimore, Maryland
  • +3 more
Oct 11, 2021

Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

Not yet recruiting
  • Nasopharyngeal and Hypopharyngeal Carcinoma
  • immunohistochemical
  • Sohag, Egypt
    Sohag University Hospital
Oct 23, 2022

Melanoma Trial in Worldwide (Relatlimab, Ipilimumab)

Active, not recruiting
  • Melanoma
  • Tucson, Arizona
  • +29 more
Dec 13, 2022

NSCLC Trial in China (Pembrolizumab, Lenvatinib, Placebo for lenvatinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Pembrolizumab
  • +2 more
  • Hefei, Anhui, China
  • +16 more
Oct 14, 2022

Regorafenib Plus Programmed Cell Death-1 Inhibitors in Advanced

Active, not recruiting
  • Advanced Colorectal Carcinoma
  • Beijing, China
    Department of Medical Oncology, Peking Union Medical College Hos
Feb 23, 2021

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023